AI for program management in drug development

The Gantt chart is not the job. The job is the register underneath it: the risks that were logged and never revisited, the vendor deliverable that quietly moved, and the action item from last month's review that nobody chased.

Program management courses will teach you scheduling. Drug development program management is mostly not a scheduling problem, which is why nothing described here is a project management application: no board, no dependency engine, no resource leveling, no shared workspace with permissions. If six people need to see and edit one plan, buy something built for that, and the biotech project management software page is the honest comparison. The timeline is usually knowable. What is not knowable, on any given Tuesday, is whether the thirty or so open commitments underneath it are still true, because they live in email threads with four different vendors and in the memory of whoever was on the call.

Running a molecule through IND-enabling work makes this concrete. The tox study sits with one contract research organization, the analytical method with another, drug substance with a third. Each has a study director who writes to you, not to a shared system. Each writes in prose, with dates buried mid paragraph. A single email can carry a report date, a change order, and a notice period on the master service agreement, and the only thing standing between those three facts and your integrated timeline is whether you read carefully at eleven at night.

What a slipped deliverable actually costs

A draft report moves by nine days. On its own that is nothing. What it means is that the review window compresses, the section that feeds the regulatory document lands after the assembly week, the stage gate has to move or be taken with an open item, and the budget line that was accrued for delivery this quarter now falls in the next one. In most companies the person who works all of that out is the program manager, at some point after it has already gone wrong.

A system built for this reads the email when it arrives, files it to the program, changes the date on the record, and follows it downstream: what depends on that date, which review has to move, which document assembly is now tight, which invoice trigger shifted. Then it drafts the reply and the internal note for you to approve. It closes what that email resolved and opens what it created. You get a decision to make rather than an evening of tracing.

The register is the product

Three things go in and never come out again in most programs. Risks get logged at kickoff with a mitigation and an owner, and are read once. Actions get captured in review minutes and are recited at the next review only if somebody scrolls back. Promises get made verbally, on a vendor call, and are never written anywhere at all.

A system that reads your transcripts and your sent mail treats all three the same way: as dated open items with a person attached. It is single seat, so when your CMC lead gives you a date that becomes a thing for you to verify rather than a task the system assigns them. It sweeps them on a schedule and brings back the ones that have come due, with the chase note already drafted in your own voice and in the context of what you and that person have already exchanged. The value is not that it writes the note. It is that the promise made on a call three weeks ago comes back on the morning it starts to matter, rather than at the review where you find out it never happened.

Contract dates behave the same way. A renewal with a sixty day notice window, a milestone that invoices on delivery, a change order that eats the contingency. Each gets a heads up scheduled before it comes due rather than on the day. For the oversight side of that relationship specifically, the build or buy question on CRO oversight is the closer read, and it covers the plan, the meeting cadence and the tooling in one place.

What that adds up to is the coordination layer around regulated work rather than the regulated work itself: the threads, the dates, the decisions and who owes what. That claim is small on purpose, and the argument for why it is nevertheless the half worth automating is on the drug development page. If you are earlier than that and just want to know what the whole category covers, start at AI for life sciences.